| Fentanyl |
№ II-2555/18.07.2008 |
Victanyl 100 micrograms/h transdermal patches x 5, Transdermal patch, 100, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
113.79 |
22.76 |
136.55 |
6% |
6.83 |
120.62 |
24.12 |
144.74 |
18% |
20.48 |
141.1 |
28.22 |
169.32 |
|
КЦ-658/05.03.2009 |
19.03.2009 |
19.03.2009 |
Неактивен |
1663 |
| Fentanyl |
№ II-2555/ 18.07.2008 |
Victanyl 25 micrograms/h transdermal patches x 5, Transdermal patch, 25, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Group PTC ehf, Iceland |
13.03 |
2.61 |
15.64 |
6% |
0.78 |
13.81 |
2.76 |
16.57 |
18% |
2.35 |
16.16 |
3.23 |
19.39 |
промяна на обстоятелства НСР-3645/29.05.2014; цената е заличена с решение НСР-6479/18.06.2015 ( в сила от 16.07.2015 ) |
КЦРР-2430/22.02.2013 |
11.03.2013 |
11.03.2013 |
Заличен |
1661 |
| Fentanyl |
№ II-2555/ 18.07.2008 |
Victanyl 25 micrograms/h transdermal patches x 5, Transdermal patch, 25, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
18.33 |
3.67 |
22 |
6% |
1.1 |
19.43 |
3.89 |
23.32 |
18% |
3.3 |
22.73 |
4.55 |
27.28 |
|
КЦРР-744/07.06.2012 |
24.06.2012 |
24.06.2012 |
Неактивен |
1661 |
| Fentanyl |
№ II-2555/18.07.2008 |
Victanyl 25 micrograms/h transdermal patches x 5, Transdermal patch, 25, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
35.19 |
7.04 |
42.23 |
6% |
2.11 |
37.3 |
7.46 |
44.76 |
18% |
6.33 |
43.63 |
8.73 |
52.36 |
|
КЦ-658/05.03.2009 |
19.03.2009 |
19.03.2009 |
Неактивен |
1661 |
| Fentanyl |
№ II-2555/ 18.07.2008 |
Victanyl 50 micrograms/h transdermal patches x 5, Transdermal patch, 50, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
34.81 |
6.96 |
41.77 |
4% |
1.39 |
36.2 |
7.24 |
43.44 |
16% |
5.57 |
41.77 |
8.35 |
50.12 |
|
КЦРР-744/07.06.2012 |
24.06.2012 |
24.06.2012 |
Неактивен |
1662 |
| Fentanyl |
№ II-2555/18.07.2008 |
Victanyl 50 micrograms/h transdermal patches x 5, Transdermal patch, 50, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
63.53 |
12.71 |
76.24 |
6% |
3.81 |
67.34 |
13.47 |
80.81 |
18% |
11.44 |
78.78 |
15.76 |
94.54 |
|
КЦ-658/05.03.2009 |
19.03.2009 |
19.03.2009 |
Неактивен |
1662 |
| Fentanyl |
№ II-2555/ 18.07.2008 |
Victanyl 75 micrograms/h transdermal patches x 5, Transdermal patch, 75, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
33.99 |
6.8 |
40.79 |
4% |
1.36 |
35.35 |
7.07 |
42.42 |
16% |
5.44 |
40.79 |
8.16 |
48.95 |
|
КЦРР-2432/22.02.2013 |
11.03.2013 |
11.03.2013 |
Неактивен |
2767 |
| Fentanyl |
№ II-2555/ 18.07.2008 |
Victanyl 75 micrograms/h transdermal patches x 5, Transdermal patch, 75, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
54.98 |
11 |
65.98 |
4% |
2.2 |
57.18 |
11.44 |
68.62 |
16% |
8.8 |
65.98 |
13.2 |
79.18 |
|
КЦРР-744/07.06.2012 |
24.06.2012 |
24.06.2012 |
Неактивен |
2767 |
| Fentanyl |
№ II-2555/18.07.2008 |
Victanyl 75 micrograms/h transdermal patches x 5, Transdermal patch, 75, mcg/h, Pack: 5 |
Actavis Group PTC ehf., Исландия |
Actavis Nordic A/S, Denmark |
92.32 |
18.46 |
110.78 |
6% |
5.54 |
97.86 |
19.57 |
117.43 |
18% |
16.62 |
114.48 |
22.9 |
137.38 |
|
КЦ-658/05.03.2009 |
19.03.2009 |
19.03.2009 |
Неактивен |
2767 |
| Liraglutide |
EU/1/09/529/003 |
Victoza, Solution for injection, 6 mg/ ml - 3 ml, mg, Pack: 3 |
Novo Nordisk A/S, Дания |
Novo Nordisk a/s Denmark |
259.66 |
51.93 |
311.59 |
4% |
10 |
269.66 |
53.93 |
323.59 |
16% |
25 |
294.66 |
58.93 |
353.59 |
|
НСР-1688/11.11.2013 |
29.11.2013 |
29.11.2013 |
Неактивен |
2269 |
| Liraglutide |
EU/1/09/529/003 |
Victoza, Solution for injection, 6 mg/ ml - 3 ml, mg, Pack: 3 |
Novo Nordisk A/S, Дания |
Novo Nordisk a/s Denmark |
260.52 |
52.1 |
312.62 |
4% |
10 |
270.52 |
54.1 |
324.62 |
16% |
25 |
295.52 |
59.1 |
354.62 |
|
КЦ-2544/09.08.2011 |
23.08.2011 |
23.08.2011 |
Неактивен |
2269 |
| Liraglutide |
EU/1/09/529/003 |
VICTOZA, Solution for injection, 6 mg/ml - 3 ml, -, Pack: 3 pre-filled pens |
Novo Nordisk A/S, Дания |
Novo Nordisk a/s Denmark |
242.21 |
48.44 |
290.65 |
4% |
9.69 |
251.9 |
50.38 |
302.28 |
16% |
25 |
276.9 |
55.38 |
332.28 |
|
НСР-7853/15.01.2016.; НСР-12221/03.04.2017; НСР-17686/09.01.2019 предварително изпълнение |
09.01.2019 |
02.02.2019 |
Активен |
2269 |
| Liraglutide |
EU/1/09/529/003 |
VICTOZA, Solution for injection, 6 mg/ml - 3 ml, -, Pack: 3 pre-filled pens |
Novo Nordisk A/S, Дания |
Novo Nordisk a/s Denmark |
255.57 |
51.11 |
306.68 |
4% |
10 |
265.57 |
53.11 |
318.68 |
16% |
25 |
290.57 |
58.11 |
348.68 |
|
НСР-7853/15.01.2016.; НСР-12221/03.04.2017 |
18.04.2017 |
02.05.2017 |
Неактивен |
2269 |
| Liraglutide |
EU/1/09/529/003 |
VICTOZA, Solution for injection, 6 mg/ml - 3 ml, -, Pack: 3 pre-filled pens |
Novo Nordisk A/S, Дания |
Novo Nordisk a/s Denmark |
259.46 |
51.89 |
311.35 |
4% |
10 |
269.46 |
53.89 |
323.35 |
16% |
25 |
294.46 |
58.89 |
353.35 |
|
НСР-7853/15.01.2016. |
02.02.2016 |
02.02.2016 |
Неактивен |
2269 |
| Boceprevir |
EU/1/11/704/001 |
Victrelis, Capsule, hard, 200, mg, Pack: 336 |
Merck Sharp & Dohme Ltd., Обединено Кралство |
S-P Labo NV Industriepark 30 B-2220 Heist-opden-Berg, Белгия |
4004.62 |
800.92 |
4805.54 |
4% |
10 |
4014.62 |
802.92 |
4817.54 |
16% |
25 |
4039.62 |
807.92 |
4847.54 |
|
НСР-8522/16.03.2016; НСР-11738/10.02.2017 |
31.03.2016 |
02.03.2017 |
Заличен |
3420 |
| Boceprevir |
EU/1/11/704/001 |
Victrelis, Capsule, hard, 200, mg, Pack: 336 |
Merck Sharp & Dohme Ltd., Обединено Кралство |
S-P Labo NV Industriepark 30 B-2220 Heist-opden-Berg, Белгия |
4004.62 |
800.92 |
4805.54 |
4% |
10 |
4014.62 |
802.92 |
4817.54 |
16% |
25 |
4039.62 |
807.92 |
4847.54 |
|
НСР-8522/16.03.2016 |
31.03.2016 |
31.03.2016 |
Неактивен |
3420 |
| Boceprevir |
EU/1/11/704/001 |
Victrelis, Capsule, hard, 200, mg, Pack: 336 |
Merck Sharp & Dohme Ltd., Обединено Кралство |
S-P Labo NV Industriepark 30 B-2220 Heist-opden-Berg, Белгия |
4004.62 |
800.92 |
4805.54 |
4% |
10 |
4014.62 |
802.92 |
4817.54 |
16% |
25 |
4039.62 |
807.92 |
4847.54 |
|
НСР-8522/16.03.2016 |
31.03.2016 |
31.03.2016 |
Неактивен |
3420 |
| Boceprevir |
EU/1/11/704/001 |
Victrelis, Capsule, hard, 200, mg, Pack: 336 |
Merck Sharp & Dohme Ltd., Обединено Кралство |
S-P Labo NV Industriepark 30 B-2220 Heist-opden-Berg, Белгия |
4831.13 |
966.23 |
5797.36 |
4% |
10 |
4841.13 |
968.23 |
5809.36 |
16% |
25 |
4866.13 |
973.23 |
5839.36 |
Оставена без разглеждане жалба от Комисия по прозрачност КП-115/03.12.2014 |
НСР-4659/25.09.2014 |
16.12.2014 |
16.12.2014 |
Неактивен |
3420 |
| Boceprevir |
EU/1/11/704/001 |
Victrelis, Capsule, hard, 200, mg, Pack: 336 |
Merck Sharp & Dohme Ltd., Обединено Кралство |
S-P Labo NV Industriepark 30 B-2220 Heist-opden-Berg, Белгия |
5577.64 |
1115.53 |
6693.17 |
4% |
10 |
5587.64 |
1117.53 |
6705.17 |
16% |
25 |
5612.64 |
1122.53 |
6735.17 |
|
НСР-257/25.06.2014 |
30.07.2013 |
30.07.2013 |
Неактивен |
3420 |
| Azacitidine |
EU/1/08/488/001 |
Vidaza, powder for suspension for injection, 25 mg/ml, mg, Pack: 1 vial x 100 mg |
Celgene Europe B.V., Нидерландия |
Baxter Oncology GmbH, Kantstrasse 2, 33790 Halle/Westfalen, Германия; Celgene Europe Ltd, 1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB, Обединено кралство |
591.97 |
118.39 |
710.36 |
4% |
10 |
601.97 |
120.39 |
722.36 |
16% |
25 |
626.97 |
125.39 |
752.36 |
Промяна на обстоятелствата НСР-16994/12.10.2018 |
НСР-7647/01.12.2015 (допуска предварително изпълнение); НСР-10740/27.10.2016 |
11.11.2016 |
02.11.2018 |
Активен |
4121 |
| Azacitidine |
EU/1/08/488/001 |
Vidaza, powder for suspension for injection, 25 mg/ml, mg, Pack: 1 vial x 100 mg |
Celgene Europe Limited, Обединено кралство, Обединено Кралство |
Baxter Oncology GmbH, Kantstrasse 2, 33790 Halle/Westfalen, Германия; Celgene Europe Ltd, 1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB, Обединено кралство |
591.97 |
118.39 |
710.36 |
4% |
10 |
601.97 |
120.39 |
722.36 |
16% |
25 |
626.97 |
125.39 |
752.36 |
|
НСР-7647/01.12.2015 (допуска предварително изпълнение); НСР-10740/27.10.2016 |
11.11.2016 |
02.12.2016 |
Неактивен |
4121 |
| Azacitidine |
EU/1/08/488/001 |
Vidaza, powder for suspension for injection, 25 mg/ml, mg, Pack: 1 vial x 100 mg |
Celgene Europe Limited, Обединено кралство, Обединено Кралство |
Baxter Oncology GmbH, Kantstrasse 2, 33790 Halle/Westfalen, Германия; Celgene Europe Ltd, 1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB, Обединено кралство |
622.62 |
124.52 |
747.14 |
4% |
10 |
632.62 |
126.52 |
759.14 |
16% |
25 |
657.62 |
131.52 |
789.14 |
|
НСР-7647/01.12.2015 (допуска предварително изпълнение) |
02.12.2015 |
02.12.2015 |
Неактивен |
4121 |
| Didanosine |
II-0684/27.09.2007 |
VIDEX EC, Gastro resistant capsule, hard, 400, mg, Pack: 30 |
Bristol-Myers Squibb Kft, Унгария |
Bristol-Myers Squibb, Champ “Lachaud”, La Goualle, F19250 Meymac, France |
232.47 |
46.49 |
278.96 |
4% |
9.3 |
241.77 |
48.35 |
290.12 |
16% |
25 |
266.77 |
53.35 |
320.12 |
|
КЦРР-1000/23.07.2012; НСР-9745/14.07.2016 |
07.08.2012 |
02.08.2016 |
Заличен |
1291 |
| Didanosine |
II-0684/27.09.2007 |
VIDEX EC, Gastro resistant capsule, hard, 400, mg, Pack: 30 |
Bristol-Myers Squibb Kft, Унгария |
Bristol-Myers Squibb, Champ “Lachaud”, La Goualle, F19250 Meymac, France |
232.47 |
46.49 |
278.96 |
4% |
9.3 |
241.77 |
48.35 |
290.12 |
16% |
25 |
266.77 |
53.35 |
320.12 |
|
КЦРР-1000/23.07.2012 |
07.08.2012 |
07.08.2012 |
Неактивен |
1291 |
| Didanosine |
II-0681/27.09.2007 |
VIDEX EC, Gastro resistant capsule, hard, 250, mg, Pack: 30 |
Bristol-Myers Squibb Kft, Унгария |
Bristol-Myers Squibb, Champ “Lachaud”, La Goualle, F19250 Meymac, France |
145.3 |
29.06 |
174.36 |
4% |
5.81 |
151.11 |
30.22 |
181.33 |
16% |
23.25 |
174.36 |
34.87 |
209.23 |
|
КЦРР-1000/23.07.2012; НСР-9746/14.07.2016 |
07.08.2012 |
02.08.2016 |
Заличен |
1290 |